Our Focus
We are committed to Providing Therapeutic Solutions that heal and improve patient outcomes.
We are committed to
Providing Therapeutic Solutions that heal and improve patient outcomes.
2
2
Patents Filled
Patents Filled
10+
10+
Partnerships
Partnerships
500+
500+
Established Network Professionals
Network Professionals
We Bridge The Gap
We Bridge The Gap
Less than 10 percent of new drug trials are successfully brought to market* despite the billions of dollars invested into their development. Such failure rate has been attributed to issues such as lack of commercial need, unmanageable toxicity, and poor strategic planning.**
At Sanare, we believe these challenges can be avoided with the proper management and support.
Less than 10 percent of new drug trials are successfully brought to market* despite the billions of dollars invested into their development. Such failure rate has been attributed to issues such as lack of commercial need, unmanageable toxicity, and poor strategic planning.**
At Sanare, we believe these challenges can be avoided with the proper management and support.
Our Expertise
Lipid-Based Molecules
Drug Repurposing
Toxicity
Brain Health
Our Expertise
Lipid-Based Molecules
Toxicity
Drug Repurposing
Brain Health
Lipid-Based Molecules
Drug Repurposing
Toxicity
Brain Health
*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173933/
** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173933/
** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
Flagship Focus
Acute Cannabinoid Intoxication (ACI) and
Cannabinoid Hyperemesis Syndrome (CHS)
According to a 2023 survey* 17% of Americans report to using cannabis, with 48% of users reporting to daily consumption.
Of these daily consumers, 32% report symptoms of CHS. Based on these numbers, it is expected that 8.7M Americans experience CHS symptoms every year.
However, there still remains no approved treatment, only symptom management.
According to a 2023 survey* 17% of Americans report to using cannabis, with 48% of users reporting to daily consumption.
Of these daily consumers, 32% report symptoms of CHS. Based on these numbers, it is expected that 8.7M Americans experience CHS symptoms every year.
However, there still remains no approved treatment, only symptom management.
*Cannabis Consumer Report by Drive Research
CHS Patient Lifetime Financial Burden
CHS Patient Lifetime Financial Burden
CHS Patient Lifetime
Financial Burden
Due to repeated hospital visits, extensive tests, and unnecessary procedures.
Due to repeated hospital visits, extensive tests, and unnecessary procedures.
Annual Cost to Hospitals per CHS Patient
Annual Cost to Hospitals per CHS Patient
CHS Patient Lifetime
Financial Burden
Strains hospital resources, diverts attention from other critical cases, and ultimately impacts overall healthcare quality.
Strains hospital resources, diverts attention from other critical cases, and ultimately impacts overall healthcare quality.
Flagship Focus
Market
The Drug Enforcement Administration (DEA) recently announced their decision to deschedule cannabis, removing it from the list of controlled substances under the Controlled Substances Act (CSA).
As of 2023, 24 states have legalized cannabis and this number is expected to grow as more states consider their own marijuana policies in light of this federal development decision.
ACI and CHS cases are expected to increase with legalization, emphasizing the urgent need for an approved treatment.
The Drug Enforcement Administration (DEA) recently announced their decision to deschedule cannabis, removing it from the list of controlled substances under the Controlled Substances Act (CSA).
As of 2023, 24 states have legalized cannabis and this number is expected to grow as more states consider their own marijuana policies in light of this federal development decision.
ACI and CHS cases are expected to increase with legalization, emphasizing the urgent need for an approved treatment.
Partner with Sanare
Flagship Focus
Market
The Drug Enforcement Administration (DEA) recently announced their decision to deschedule cannabis, removing it from the list of controlled substances under the Controlled Substances Act (CSA).
As of 2023, 24 states have legalized cannabis and this number is expected to grow as more states consider their own marijuana policies in light of this federal development decision.
ACI and CHS cases are expected to increase with legalization, emphasizing the urgent need for an approved treatment.